Brightmeds NAD+ Review – The Headline Price Is a First Month

What It Is and Who It Is For

Brightmeds sells compounded NAD+ as a subcutaneous injection through a telehealth consultation, marketed for energy, recovery, mental clarity and anti-aging.

The page advertises “from $105/mo.” The real range, once you read the plan table and annualise it, is roughly $1,810 to $2,902 a year.

This is the second Brightmeds product we have reviewed and the second NAD+ service, so we re-ran every regulatory and evidence check from scratch rather than relying on the earlier work. Everything below was verified on 8 August 2026.

Read This First

The Headline Price Is a First Month

The page title, the hero and the meta description all say the same thing: “NAD+ Injections from $105/mo.”

The footnote, in small print near the compounding disclosure, says:

And the plan table itself says something narrower still. On the 12-Month plan, $105 is the first month only — after that it is $155 a month.

To be precise about the $50: it is real and consistently applied. Every plan’s first month is its standard rate minus roughly $50 — $155 becomes $105, $246 becomes $196. The arithmetic checks out. It is a one-off first-order discount, not a rate.

The section containing this table is headed “Transparent pricing you can trust.” The table genuinely is transparent — all four plans, both prices, billing and shipping frequency, clearly laid out. It is the headline above it that is doing the work.

All Four Plans, Annualised

Here is what the table says, and what it costs over a year — applying the one-off $50 discount once, then eleven months at the standard rate.

The spread is about $1,092. Choosing the monthly plan over the twelve-month plan costs you roughly 60% more over a year — which is the incentive doing its job, and it is a steep one.

Note also that billing and shipping run on different clocks. All plans except the monthly one ship every two months — so on the twelve-month plan you pay once and receive six deliveries. Keep your own record of what has arrived against what you paid for.

The Cheapest Plan Wants the Year Up Front

This is where the pricing structure meets the contract, and the combination matters.

The 12-Month plan is “Billed every 12 months.” So the cheapest route to that headline price is a single charge of roughly $1,810.

Now read that against Brightmeds’ Terms of Service, which state that fees and charges “are non-refundable, either in whole or in part.”

That is a large, irreversible commitment for a compounded product with essentially no randomised evidence in people like you. If you are going to try this at all, the shorter plans cost more per month precisely because they carry less risk — and on an unevidenced product, paying for optionality is a defensible trade.

The Guarantee Got Narrower

We reviewed a different Brightmeds product recently and noted its guarantee was unusually narrow. This page’s is narrower still.

A “100% money back guarantee if your prescription is not approved” refunds you for a transaction that never happened. If the clinician says no, you get your money back — which is not a guarantee so much as the absence of a charge for nothing.

Twelve States Cannot Order This

A concrete eligibility restriction, straight from the advertiser’s own terms. Subcutaneous products are prohibited in twelve states:

NAD+ here is a subcutaneous injection, so that is the list that applies to it. A separate, shorter restriction covers semaglutide, tirzepatide, sildenafil and tadalafil in Alabama, Arkansas, Louisiana, Mississippi and South Carolina.

Check your state before you start an intake, and think about it before committing to a twelve-month prepayment — because moving to a restricted state mid-plan is exactly the scenario the non-refundable clause would bite in.

Still No FDA-Approved NAD+

We re-ran this check from scratch rather than citing our earlier work.

Brightmeds says so themselves, clearly and more than once — their compounding paragraph states that compounded pharmaceuticals “are not FDA-approved.” We are confirming they are right, not catching them out.

What compounded means, once more: lawful when a licensed pharmacy prepares a medicine for an individual patient against a prescription, but FDA does not review the formulation for safety, effectiveness or manufacturing quality before it is sold.

The Evidence, Re-Checked

Same discipline: re-run, not recalled.

A PubMed search for randomised controlled trials of NAD+ given by injection, infusion or subcutaneously, in humans, returned four records. The identical query form returns 294 for semaglutide — so the method is sound.

Two fair qualifications. A 2026 placebo-controlled trial existing at all shows serious researchers take NAD biology seriously — this is not fringe. And absence of evidence is not evidence of absence. Nobody has shown these injections do nothing; they have not shown they do something, in people like you.

The page’s own language is worth noticing. Some claims are properly hedged — “May help improve mental clarity and focus,” “Can promote improved skin quality” — while others are flat assertions: “Improves Energy and Recovery,” “Promotes Anti-Aging and Vitality.” Given the trial base, the hedged versions are the honest ones.

The Injection Argument

Their FAQ makes the standard case: “Why get a shot instead of pills? NAD+ is not absorbed as effectively in pill form.”

That half is fair. Oral NAD+ is largely degraded in the gut, and injecting bypasses that. No argument.

But bypassing your gut is not the same as reaching your cells, and NAD+ works inside cells. Here is the molecule, from PubChem:

It misses on all three, and not narrowly. An XLogP of −6 describes a molecule that strongly prefers water to fat — and a cell membrane is fat. The generally understood route is that circulating NAD+ is broken down outside the cell into smaller precursors, which are transported in and rebuilt.

To be precise about what that is: our reading of published physicochemical properties, not a finding from a trial of this product. It does not prove the injections do nothing. It does mean the mechanism implied by “deliver it directly” is one the molecule’s own properties argue against — and the precursors it likely becomes are available orally, over the counter, where most of the human trial data actually sits.

What Brightmeds Gets Right

Stating this properly, because it remains true across both their pages we have read.

• The compounding disclosure is the best in this category. Not a footnote — a paragraph stating compounded products “are not FDA-approved” and adding that “it might be challenging to directly compare the results and risk profiles of FDA-approved and compounded pharmaceuticals due to differences in strength, dose, and other factors”
• The plan table is genuinely complete — four plans, both price points, billing frequency and shipping frequency. Our criticism is the headline above it, not the table
• They state clearly that they are not the provider: “brightmeds.com does not directly offer medical or pharmacy services. We partner with medical professionals who use HIPAA-compliant platforms”
• FSA/HSA eligible, which at these prices meaningfully softens the cost with pre-tax dollars
• The $50 first-order discount is real and applied consistently across every plan
• They direct readers to “contact your doctor if you have any questions or concerns regarding your health”

Safety and Who Should Not Use This

We found no contraindication list on this landing page, which is thin for a product you inject into yourself repeatedly.

Sensible cautions to raise with a clinician:

• Do not use if pregnant or breastfeeding — there is no safety data supporting it
• If you have active or previous cancer, discuss it with your oncologist first. NAD metabolism intersects with tumour metabolism and the science there is genuinely unsettled
• Any self-injection carries risk of bruising, injection-site reactions and infection with poor technique. Get shown how, and dispose of sharps properly
• Intravenous NAD+ is widely reported to cause chest tightness, nausea and flushing when infused quickly. Subcutaneous dosing differs, but the molecule is not inert
• Tell the prescriber every medication and supplement you take, and be candid at intake
• If you are persistently exhausted, get it investigated. Fatigue has findable causes — thyroid disease, anaemia, sleep apnoea, depression, low testosterone — and the real risk of a product like this is delay, not harm

How It Compares

The third column is the one that matters most. Persistent fatigue and brain fog are symptoms with causes that can be found and treated. The principal risk here is not that the injections hurt you — it is that spending $1,810 delays somebody from finding out why they are exhausted.

Who Should Consider It and Who Should Not

It may reasonably suit you if you:

• Have already had fatigue properly investigated and come back clear
• Understand you are buying an untrialled compounded product and are genuinely comfortable with that
• Can treat $1,810 to $2,902 a year as discretionary, knowing it is not refundable
• Are comfortable self-injecting and have discussed it with your own clinician
• Live outside the twelve restricted states, and expect to stay there

Do not buy this if you:

• Are tempted by “$105/mo.” That is one discounted month on a plan that bills about $1,810 at once
• Would be committing money you could not afford to lose, since fees are non-refundable in whole or in part
• Have active or previous cancer, without an oncologist’s view first
• Are pregnant or breastfeeding
• Live in Alabama, Alaska, Delaware, Hawaii, Louisiana, Massachusetts, Mississippi, Missouri, Rhode Island, South Carolina, Wisconsin or Wyoming — subcutaneous products are prohibited there
• Have unexplained fatigue that has not been worked up. Start with a clinician and a blood test

Pros and Cons

Limitations of This Review

Our general web search was unavailable, so this comes from the Brightmeds NAD+ landing page and their published terms, plus the FDA Drugs@FDA database, PubMed via NCBI E-utilities and PubChem — all read on 8 August 2026.

We could not reach Trustpilot, the BBB or Reddit — the page displays Trustpilot branding and we could not verify any rating — so we have no independent customer data on delivery, the substance of the consultation, or whether anyone reports benefit.

We did not complete an intake or purchase, so we have not seen the prescribing questions, the compounding pharmacy, a certificate of analysis, the prescribed dose or concentration, or the checkout screens. Our annualised figures are our own arithmetic on their published table, applying the $50 discount once — confirm the actual charge at checkout before agreeing.

The state restrictions come from the advertiser’s own terms as supplied to us, not from the consumer-facing site, and restrictions of this kind change — verify at intake. Our literature searches are one database, one query form, one day, and PubMed does not index everything. The membrane-permeability discussion is interpretation of published physicochemical properties, not a measurement of what this product does in a body. We are not clinicians and this is not medical advice.

Frequently Asked Questions

Verdict

Brightmeds remains better than most of this category at disclosure. Their compounding paragraph is the most thorough we have read, they say plainly that compounded products are not FDA-approved, and their plan table is complete — four options, both price points, billing and shipping frequency, all of it there.

The problem sits directly above that table. “NAD+ Injections from $105/mo” is not a monthly price. It is the discounted first month of the twelve-month plan, after which it is $155 — an average of about $151 a month, or $1,810 for the year, billed in one payment.

And their terms say fees are “non-refundable, either in whole or in part.” So the cheapest advertised route is also the one that puts $1,810 beyond recall before you know whether it does anything — with a guarantee that covers only the doctor declining to prescribe.

Meanwhile, re-checked from scratch: there is no FDA-approved NAD+ product, and no randomised trial of injected NAD+ in healthy adults for energy, clarity or anti-aging — while the same search returns 294 trials for semaglutide.

If you are going to try this, do not take the twelve-month plan. The shorter plans cost more per month, and on a product with no evidence base that is exactly what you should be paying for — the ability to stop.

And if you are tired, start with a clinician and a blood test, not a year’s supply of anything.